Status:
COMPLETED
Economic Evaluation of Vancomycin Therapeutic Drug Monitoring Methods
Lead Sponsor:
Hamad Medical Corporation
Collaborating Sponsors:
Qatar University
Conditions:
Infection, Bacterial
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Vancomycin is a widely used antibiotic in the treatment of complicated gram positive infections. Approaches to vancomycin therapeutic drug monitioring (TDM) vary. This clinical trial aimed to compare ...
Eligibility Criteria
Inclusion
- adults at least 18 yrs who are hospitalized and initiated on IV vancomycin
Exclusion
- renal instability
- immunosuppression;
- vancomycin allergy;
- history of recurrent peritonitis
- administration of \< 4 doses of vancomycin
- pregnancy;
- hemoglobin \< 8 g/dL.
Key Trial Info
Start Date :
January 23 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 2 2021
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT04297176
Start Date
January 23 2020
End Date
July 2 2021
Last Update
August 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hamad Medical Corporation
Doha, Qatar